If it ain't broke, don't price fix it the oft and the PPRS

Health Economics

Volumn 16, Issue 7, 2007, Pages 653-665

  Towse, Adrian ^a  

^a Office of Health Economics   (United Kingdom)

Author keywords

Cost effectiveness; Pharmaceuticals; Profit control; Regulation; Value of information

Indexed keywords

CONTINGENT VALUATION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; GOVERNMENT REGULATION; HEALTH CARE FINANCING; HEALTH ECONOMICS; NATIONAL HEALTH SERVICE; PATENT; PRIORITY JOURNAL; PROFIT; QUALITY ADJUSTED LIFE YEAR; REVIEW; UNITED KINGDOM; VALIDATION PROCESS;

COMMERCE; COSTS AND COST ANALYSIS; DRUG INDUSTRY; ECONOMICS, PHARMACEUTICAL; GOVERNMENT REGULATION; GREAT BRITAIN; INTERNATIONALITY; QUALITY-ADJUSTED LIFE YEARS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 34447622690     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.1263     Document Type: Review

References (43)

1. Acemoglu D, Linn J. Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry. Massachusetts Institute of Technology: Cambridge, MA, 2003; Working Paper 03-33, Massachusetts Institute of Technology, Department of Economics Working Paper Series.
2. Adelphi Consulting. 2006. Qualitative Analysis of Variation in Uptake of Medicines across the NHS in England. A Report prepared for the Technical Group of the Partnership Workstream of the Ministerial Industry Strategy Group. Department of Health and Association of the British Pharmaceutical Industry. http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/ DH_065198
3. Averch H, Johnson L. 1962. Behaviour of the firm under regulatory constraint. American Economic Review 52: 1052-1069.
4. Bloom N, Van Reenen J. 1998. Regulating drug prices: where do we go from here? Fiscal Studies 19: 321-342.
5. Buxton M. 2006. Economic evaluation and decision making in the United Kingdom. PharmacoEconomics 24: 1133-1142.
6. Cave M, Towse A. 1997. Regulating Prices Paid by the NHS for Medicines Supplied by the UK-Based Pharmaceutical Industry. Briefing No. 34. Office of Health Economics: London.
7. Claxton K. 2007. OFT, VBP: QED? Health Economic 16(6): 545-558.
8. Cockburn I. 2004. The changing structure of the pharmaceutical industry. Health Affairs 23(1): 10-22.
9. Cooksey D. 2006. A Review of UK Health Research Funding. The Stationery Office: London.
10. Culyer AJ, McCabe C, Briggs A, Claxton K, Buxton M, Akehurst R, Sculpher M, Brazier J. 2007. Searching for a threshold, not setting one: the role of the National Institute of Health and Clinical Excellence. Journal of Health Services Research and Policy 12(1): 56-58.
11. Danzon PM, Furukawa MF. 2006. Prices and availability of biopharmaceuticals: an international comparison. Health Affairs 25(5): 1353-1362.
12. Department of Health. 2004. The Pharmaceutical Price Regulation Scheme 2005. Department of Health: London.
13. Department of Health and the Association of the British Pharmaceutical Industry. 2002. PPRS: The Study into the Extent of Competition in the Supply of Branded Medicines to the NHS. Department of Health: London.
14. DiMasi J, Paquette C. 2004. The economics of follow-on drug research and development, trends in entry rates and the timing of development. PharmacoEconomics 22(2): 1-14.
15. DiMasi JA, Hansen RW, Grabowski HG. 2003. The price of innovation: new estimates of drug development costs. Journal of Health Economics 22: 151-185.
16. DotEcon. 2004. Assessing the impact of public sector procurement on competition. Report for the Office of Fair Trading, vol. 1. Office of Fair Trading, London, OFT742a, September.
17. Edwards JSS, Kay JA, Mayer CP. 1987. The Economic Analysis of Accounting Profitability. Oxford University Press: Oxford.
18. Finkelstein A. 2003. Health policy and technological change: evidence from the vaccine industry. NBER Working Paper No. 9460, National Bureau of Economic Research, Cambridge, MA.
19. Garrison L, Towse A. 2003. The drug budget silo mentality in Europe: an overview. Value in Health 6(s1): S1-S9.
20. Grabowski H, Vernon J, Di Masi J. 2002. Returns on research and development for 1990s new drug introductions. PharmacoEconomics 20(3): 11-29.
21. Griffin S, Claxton K, Palmer S, Sculpher MJ. 2007. Dangerous omissions: the consequences of ignoring decision uncertainty. Medical Decision Making 27(1): E8.
22. Keyworth T, Yarrow G. 2007. Review of the Office of Fair Trading's Market Study of the Pharmaceutical Price Regulation Scheme. Regulatory Policy Institute: Oxford.
23. Kind P. forthcoming. Putting the 'Q' in QALYs. In The Influence of Alan Williams, Mason A, Towse A (eds). Radcliffe: Oxford.
24. LFN (Pharmaceutical Benefits Board). 2007. The Swedish Pharmaceutical Reimbursement System - A Brief Overview. LFN: Solna.
25. Lichtenberg FR, Walsfogel J. 2003. Does misery love company? Evidence from pharmaceutical markets before and after the Orphan Drug Act. Working Paper 9750, National Bureau of Economic Research, Cambridge, MA.
26. Murphy KM, Topel RH (eds). 2003. Measuring the Gains from Medical Research: An Economic Approach. The University of Chicago Press: Chicago.
27. Myers S. 1999. Measuring pharmaceutical risk and the cost of capital. In Risk and Return in the Pharmaceutical Industry, Sussex J, Marchant N (eds). Office of Health Economics: London; 59-76.
28. NAO Report. 2007. Prescribing Costs in Primary Care. Report by the Comptroller and Auditor General, HC 454 Session 2006-7, The Stationery Office, London, May.
29. NERA. forthcoming. Key Factors in Attracting Internationally Mobile Investments by the Research-Based Pharmaceutical Industry. Report to the UK Ministerial Industry Strategy Group. http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/ DH_065198
30. Office of Fair Trading. 2007a. The Pharmaceutical Price Regulation Scheme. An OFT Market Study. Office of Fair Trading: London.
31. Office of Fair Trading. 2007b. Annexe I modelling of profitability. The Pharmaceutical Price Regulation Scheme. An OFT Market Study. Office of Fair Trading: London.
32. OHE Consulting. 2005. The Many Faces of Innovation. A Report for The European Federation of Pharmaceutical Industries and Associations (EFPIA). OHE Consulting: London. http//:www.efpia.org/Objects/2/Files/ Manyfacesofinnovation.pdf
33. Pammolli F, Riccaboni M. 2004. Market structure and drug innovation. Health Affairs 23: 48-50.
34. Philipson TJ, Jena AB. 2005. Who benefits from new medical technologies? Estimates of consumer and producer surpluses for HIV/AIDS drugs. Forum for Health Economics & Policy 9: Article 3. http://www.bepress.com/fhep/biomedical_research/3
35. Ryan M, Yule B, Bond C, Taylor R. 1992. Knowledge of drug costs: a comparison of general practitioners in Scotland and England. British Journal of General Practice 42: 6-9.
36. Ryan M, Yule B, Bond C, Taylor R. 1996. Do physicians perceptions of drug costs influence their prescribing. Pharmacoeconomics 9: 321-331.
37. Shliefer A. 1985. A theory of yardstick competition. Rand Journal of Economics 16: 319-327.
38. Silcock J, Ryan M, Bond C, Taylor R. 1997. Changes in Scottish general practitioners attitudes and knowledge in respect of prescribing costs between 1986 and 1995. European Journal of General Practice 2: 168-170.
39. Towse A, Buxton M. 2006. Notes on a Conference in Honour of Bernie O'Brien. Three Challenges to Achieving Better Analysis for Better Decisions: Generalisability, Complexity and Thresholds. OHE Briefing No. 42. Office of Health Economics: London.
40. Towse A, Leighton T. 1999. The changing nature of NCE pricing of second and subsequent entrants. In Risk and Return in the Pharmaceutical Industry, Sussex J, Marchant N (eds). Office of Health Economics: London; 91-105.
41. Vickers J, Yarrow G. 1988. Privatisation. An Economic Analysis. The MIT Press: Cambridge, MA.
42. Wertheimer A, Levy R, O'Connor T. 2001. Too many drugs? The clinical and economics value of incremental innovations. Investing in Health: The Social and Economic Benefits of Health Care Innovation 14: 77-118
43. Wren-Lewis S. 2003. Estimates of Equilibrium Exchange Rates for Sterling Against the Euro. EMU Study. HM Treasury, London.